Emergent commences TRU-016 Phase 2 study in leukemia patients
TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies. Emergent will be entitled to a milestone payment of $6m with the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.